#ACR23 Late-Breaking Abstr#L13 CAR-T is in CT but not RCT yet. Preliminary results from open label (N=3 #SLE of YTB323 (rapcabtagene autocel CD19 directed with preserved T cell stemness) showed favourable CAR T expansion, B cell depletion, early efficacy & safety @RheumNow https://t.co/UQUOfDbFJe

A#2316 #ACR23 @RheumNow 91 SLE pts w COVID v 182 SLE wo COVID ifn 11 SLE/COVID: serious disease 1 death, 7 severe compl W/in 90d, 15% mild/mod SLE flare 2% severe SLE flare Flare rate 17.6% higher than no COVID ifn 5% p=0.001 High HV ifn (2% v 1%) dsDNA/C3 changes not signif diff https://t.co/dxGJNNWuFy

A#2313 #ACR23 @RheumNow Utilization of inpt palliative care incr from 2016-2020 in SLE admits from 1.8% 2016 to 2.6% 2020 Pall care use incr: older pt, comorbid index, teaching, large hosps Lower use: age <35 yo, Black & Hispanic race Need to address racial disparities in utiliz https://t.co/wQ8NOhm9lK https://t.co/3tJgt4MMDf

@EricFMorand SPOCS Study: A#2263 @ACR23 826 pts - 71% high IFN gene sig Mean SLEDAI-2K lower with low IFNGS 6mo: pts reports 1+ flare 19% high IFNGS, 16% low. Both grps 6.7% LLDAS, but remission 4% low/1.7% high In 36 mo, <10% LLDAS, <10% remission @earlyARA @RheumNow https://t.co/z5v4TBVuDG

Post hoc analysis of Ph2 AURA-LV & Ph3 AURORA1 ⬆️VOC-treated pts achieved CRR at 1yr vs. control arm (41.0% vs. 21.9%; OR 2.48, p< 0.0001) and PRR at 1yr (OR 2.3, p< 0.0001) Similar safety profiles VOC: Additional tx option for LN pts w/ UPCR >/=2g/g #ACR23 ABST2326 @RheumNow https://t.co/9z1n3s7umU

A#2297 #ACR23 @RheumNow Baseline IFNα predicts complete response at 2 yrs in LN HIgh IFNα: incr risk of 2+ renal flare Increase of 1 unit of IFNα incr risk of 2+ flares by 35% & risk of decr GFR IFNα cutoff 0.6 for 2+ flare, 1.3 for progr to eGFR <15 AUC 0.6 (weak predictor) https://t.co/FKeDJVNyYj

HCQ improves complements A#2327 #ACR23 @RheumNow Petri @jhrheumatology @andreafava Pts w/ low complement & low HCQ levels In pts who increased HCQ WB level >50 ng/mL, incr in mean C3 (p=0.02) v HCQ that did not incr More nml C4 levels (p=.003) and incr mean C4 (p=.004) on HCQ https://t.co/J7PIuaRTO8

HCQ Discontinuation A#2343 #ACR23 @RheumNow 42 pts d/c HCQ 19% flared in past yr before d/c D/c reasons: retina tox 57%, self-dc 17%, other eye issue 12% 26% flare in yr after d/c - strongest ass for flare: mean C3, dsDNA+ at index visit https://t.co/d4TqneS46u

The patients’ voice matters! Watch my interview with @LAlupusLady regarding how she manages #Lupus and her perspective about the disease @rheumnow #ACR23 @uptoTate https://t.co/P9KPJQEkRv

@Bweber04 on recurrent pericarditis especially some seen in our lupus population IL-1 inhibition with Rilonacept really redefining treatment success and altering the typical treatment algorithm @RheumNow #ACR23 https://t.co/Ey1DN8eSXT